Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine Studie, um mehr über das Studienmedikament PF-07934040 zu erfahren, wenn es allein oder zusammen mit anderen Krebstherapien bei Menschen mit fortgeschrittenen soliden Tumoren verabreicht wird, die eine genetische Mutation aufweisen.

9. Oktober 2026 aktualisiert von: Pfizer

Eine offene Phase-1-Studie zu PF-07934040 als Einzelwirkstoff und in Kombination mit anderen zielgerichteten Wirkstoffen bei Teilnehmern mit fortgeschrittenen soliden Tumoren, die Mutationen im KRAS-Gen tragen

The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose.

This study is seeking participants who have solid tumors (a mass of abnormal cells that forms a lump or growth in the body) that:

  • are advanced (cancer that doesn't disappear or stay away with treatment) and
  • have a KRAS gene mutation (a change in the DNA of the KRAS gene that can cause cells to grow in very high numbers).

This includes (but limited to) the following cancer types:

Non-Small Cell Lung Cancer (NSCLC): It's a type of lung cancer where the cells grow slowly but often spread to other parts of the body.

Colorectal Cancer (CRC): This is a disease where cells in the colon (a part of large intestine) or rectum grow out of control.

Pancreatic ductal adenocarcinoma (PDAC): This is a cancer that starts in the ducts of the pancreas but can spread quickly to other parts of the body. Pancreas is a long, flat gland that lies in the abdomen behind the stomach. Pancreas creates enzymes that help with digestion. It also makes hormones that can help control your blood sugar levels.

All participants in this study will take the study medication (PF-07934040) as pill by mouth twice a day repeating for 21-day or 28-day cycles.

Depending on which part of the study participants are enrolled into they will receive the study medication (PF-07934040 alone or in combination with other anti-cancer medications). These anti-cancer medications will be given in the study clinic by intravenous (IV) that is directly injected into the veins at various times (depending on the treatment) during the 21-day or 28-day cycle.

Participants can continue to take the study medication (PF-07934040) and the combination anti-cancer therapy until their cancer is no longer responding.

The study will look at the experiences of people receiving the study medicines. This will help see if the study medicines are safe and effective.

Participants will be involved in this study for up to 4 years. During this time, they will come into the clinic between 1 to 4 times in each 21-day or 28-day cycle. After they have stopped taking the study medication (at about at 2 years) they will be followed for another two years to see how they are doing.

Studienübersicht

Status

Aktiv, nicht rekrutierend

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Tatsächlich)

64

Phase

  • Phase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Rio Piedras, Puerto Rico, 00935
        • Pan American Center for Oncology Trials, LLC
    • Arkansas
      • Fayetteville, Arkansas, Vereinigte Staaten, 72703
        • Highlands Oncology Group, PA
      • Rogers, Arkansas, Vereinigte Staaten, 72758
        • Highlands Oncology Group, PA
      • Springdale, Arkansas, Vereinigte Staaten, 72762
        • Highlands Oncology Group
    • California
      • Duarte, California, Vereinigte Staaten, 91010
        • City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
      • Duarte, California, Vereinigte Staaten, 91010
        • City of Hope Investigational Drug Service (IDS)
    • Colorado
      • Aurora, Colorado, Vereinigte Staaten, 80045
        • University of Colorado Hospital - Anschutz Outpatient Pavilion
      • Aurora, Colorado, Vereinigte Staaten, 80045
        • University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)
      • Aurora, Colorado, Vereinigte Staaten, 80045
        • University of Colorado Hospital- Anschutz Cancer Pavilion (ACP)
      • Aurora, Colorado, Vereinigte Staaten, 80045
        • University of Colorado Hospital
    • District of Columbia
      • Washington D.C., District of Columbia, Vereinigte Staaten, 20016
        • Sibley Memorial Hospital
    • Michigan
      • Grand Rapids, Michigan, Vereinigte Staaten, 49546
        • START Midwest
    • Missouri
      • City of Saint Peters, Missouri, Vereinigte Staaten, 63376
        • Siteman Cancer Center - St Peters
      • Creve Coeur, Missouri, Vereinigte Staaten, 63141
        • Siteman Cancer Center - West County
      • Florissant, Missouri, Vereinigte Staaten, 63031
        • Siteman Cancer Center - North County
      • St Louis, Missouri, Vereinigte Staaten, 63110
        • Barnes-Jewish Hospital
      • St Louis, Missouri, Vereinigte Staaten, 63110
        • Washington University School of Medicine
      • St Louis, Missouri, Vereinigte Staaten, 63129
        • Siteman Cancer Center - South County
      • St Louis, Missouri, Vereinigte Staaten, 63108
        • Siteman Cancer Center
    • North Carolina
      • Durham, North Carolina, Vereinigte Staaten, 27710
        • Duke University Medical Center
      • Durham, North Carolina, Vereinigte Staaten, 27710
        • Duke University Medical Center, lnvestigational Chemotherapy Service
    • Ohio
      • Cincinnati, Ohio, Vereinigte Staaten, 45219
        • University of Cincinnati Medical Center
      • Cleveland, Ohio, Vereinigte Staaten, 44195
        • Cleveland Clinic Taussig Cancer Center
      • West Chester, Ohio, Vereinigte Staaten, 45069
        • West Chester Hospital
    • Rhode Island
      • Providence, Rhode Island, Vereinigte Staaten, 02903
        • Rhode Island Hospital
      • Providence, Rhode Island, Vereinigte Staaten, 02906
        • Miriam Hospital
    • Texas
      • Houston, Texas, Vereinigte Staaten, 77030
        • University of Texas MD Anderson Cancer Center

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Histological or cytological diagnosis of advanced, unresectable, and/or metastatic or relapsed/refractory solid tumor.

ECOG PS 0 or 1

  • Presence of at least 1 measurable lesion based on RECIST version 1.1 that has not been previously irradiated.

  • Documentation of mutated KRAS gene

    1. PDAC, CRC, Other tumor types: Confirmed KRAS mutation, any variant
    2. NSCLC: Confirmed KRAS mutation, any variant except previously treated G12C. If driver mutation, must have failed precision medicine therapy [eg, inhibitors of epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), and others].
  • Part 1 and Part 2a: Participant must have progressed on standard treatment(s) for which no additional, effective therapy is available.

    1. PDAC (2-3L): Participants must have received and radiologically progressed on prior lines of systemic therapy for metastatic pancreatic adenocarcinoma. If participants received prior neoadjuvant or adjuvant chemotherapy and progressed within 6 months of the last dose, then this should be considered as a prior line of systemic therapy.
    2. NSCLC (2-3L): Participants must have received prior lines of anti-cancer treatment and progressed on at least a platinum-containing chemotherapy regimen or ICI. Participants may have had only one or two prior lines of therapy in the advanced/metastatic setting. For participants with EGFR, ALK, or other genomic tumor alterations, participants must have progressed on approved therapy for these alterations.
    3. CRC (2-3L): Participants must have had one or two prior lines of therapy for mCRC. For either one or two prior treatments, these regimens must have included a fluoropyrimidine, oxaliplatin, and/or irinotecan for one prior treatment, exposure to VEGF/VEGF receptor (VEGFR) inhibitor is optional;
    4. Other tumors: Participants, in the judgment of the investigator, must have progressed or become intolerant to all available standard therapies, or have refused such therapy.
  • Part 2b:

    1. PDAC (1L) Cohort A2: Participants must not have received prior chemotherapy for metastatic disease. Participant could have received neoadjuvant therapy, adjuvant therapy, or adjuvant chemo-radiotherapy. If relapse occurred within 6 months of last dose of adjuvant treatment or neoadjuvant therapy, the participant would be considered 2L, and not 1L.
    2. CRC (2-3L) Cohort B2: Participants must have had one or two prior systemic treatment regimens for mCRC. For either one or two prior treatments, these regimens must have included a fluoropyrimidine, irinotecan, oxaliplatin; for one prior treatment, exposure to a VEGF/VEGF receptor (VEGFR) inhibitor is optional.
    3. CRC (1L) Cohort B3/B4: Participants must not have received prior therapy for metastatic disease and not be a candidate for other targeted therapy or immunotherapy. Participant could have received neoadjuvant therapy, adjuvant therapy, or adjuvant chemo-radiotherapy. If relapse occurred within 6 months of last dose of adjuvant or neoadjuvant therapy, then the participant would be considered 2L, and not 1L.
    4. NSCLC (1L) Cohort C2: Participants must have a TPS ≥50% and must not have received prior systemic treatment setting.
    5. NSCLC (1L) Cohort C3: Participants with any TPS and must not have received prior systemic treatment setting.

Exclusion Criteria:

  • Active or history of pneumonitis/ILD or pulmonary fibrosis requiring treatment with systemic steroid therapy.

  • Diagnosis of immunodeficiency or an active autoimmune disease that require systemic treatment with chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy in the past 2 years.

  • Sensory peripheral neuropathy ≥Grade 2

  • Active or history of clinically significant gastrointestinal (GI) disease (including but not limited to inflammatory GI disease [eg, ulcerative colitis, Crohn's disease, inflammatory bowel disease], immune-mediated colitis, peptic ulcer disease, GI bleeding, chronic diarrhea) and other conditions that are unresolved and/or may increase the risk associated with study participation or study treatment administration.

  • Active bleeding disorder, including GI bleeding, as evidenced by hematemesis, significant hemoptysis or melena in the past 6 months.

  • Major surgery or completion of radiation therapy ≤4 weeks prior to enrollment/randomization or radiation therapy that included >30% of the bone marrow.

  • Known sensitivity or contraindication to any component of study intervention (PF 07934040, gemcitabine, nab-paclitaxel, cetuximab, bevacizumab, FOLFOX, 5-FU, pembrolizumab, cisplatin, carboplatin, pemetrexed, SHP2 inhibitor(s), cyclin-dependent kinase (CDK) inhibitor(s), antibody drug conjugates (ADCs) or EGFR inhibitor(s)).

  • Hematologic abnormalities.

  • Renal impairment.

    • Hepatic abnormalities.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Nicht randomisiert
  • Interventionsmodell: Sequenzielle Zuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Part 1

PF-07934040 Monotherapy Dose Escalation PF-07934040 monotherapy at prescribed dose and frequency in 28-day cycles

panKRAS inhibitor

Andere Namen:
  • PF-4040
Experimental: Part 2a Cohort A1

Monotherapy dose expansion in 2-3L PDAC. PF-07934040 at prescribed dose and frequency in 28-day cycles

panKRAS inhibitor

Andere Namen:
  • PF-4040
Experimental: Part 2a Cohort B1

Monotherapy dose expansion in 2-3L CRC. PF-07934040 at prescribed dose and frequency in 28-day cycles

panKRAS inhibitor

Andere Namen:
  • PF-4040
Experimental: Part 2a Cohort C1

Monotherapy dose expansion in 2-3L NSCLC. PF-07934040 at prescribed dose and frequency in 28-day cycles

panKRAS inhibitor

Andere Namen:
  • PF-4040
Experimental: Part 2a Cohort D1

Monotherapy dose expansion in Other Indications. PF-07934040 at prescribed dose and frequency in 28-day cycles

panKRAS inhibitor

Andere Namen:
  • PF-4040
Experimental: Part 2b Cohort A2

Combination (PF-07934040 + Gemcitabine + Nab-paclitaxel) dose escalation/expansion in 1L PDAC.

Prescribed dose and frequency in 28-day cycles

panKRAS inhibitor

Andere Namen:
  • PF-4040

Chemotherapy (antimetabolite)

Andere Namen:
  • Gemzar

Taxane-type Chemotherapy

Andere Namen:
  • Abraxane
Experimental: Part 2b Cohort B2

Combination (PF-07934040 + Cetuximab) dose escalation/expansion in 2-3L CRC

Prescribed dose and frequency in 28-day cycles

panKRAS inhibitor

Andere Namen:
  • PF-4040

Monoclonal Antibody (EGFR Inhibitor)

Andere Namen:
  • Erbitux
Experimental: Part 2b Cohort B3

Combination (PF-07934040 + FOLFOX + Bevacizumab) dose escalation/expansion in 1L CRC

Prescribed dose and frequency in 28-day cycles

panKRAS inhibitor

Andere Namen:
  • PF-4040

Part of FOLFOX chemotherapy regimen

cytotoxic chemotherapy (antimetabolite and pyrimidine analog)

Andere Namen:
  • 5-FU
  • 5-Fluorouracil

Part of FOLFOX Chemotherapy Regimen

platinum based compound (alkylating agent)

Andere Namen:
  • Eloxatin

Part of FOLFOX chemotherapy regimen

Folic Acid Analog

Andere Namen:
  • Wellcovorin
  • Folinsäure
  • Calciumfolinat
  • Leucovorin-Kalzium

VEG-F inhibitor

Andere Namen:
  • Avastin
  • Zirabew
Experimental: Part 2b Cohort B4

Combination (PF-07934040 + FOLFOX + Cetuximab) dose escalation/expansion in 1L CRC

Prescribed dose and frequency in 28-day cycles

panKRAS inhibitor

Andere Namen:
  • PF-4040

Monoclonal Antibody (EGFR Inhibitor)

Andere Namen:
  • Erbitux

Part of FOLFOX chemotherapy regimen

cytotoxic chemotherapy (antimetabolite and pyrimidine analog)

Andere Namen:
  • 5-FU
  • 5-Fluorouracil

Part of FOLFOX Chemotherapy Regimen

platinum based compound (alkylating agent)

Andere Namen:
  • Eloxatin

Part of FOLFOX chemotherapy regimen

Folic Acid Analog

Andere Namen:
  • Wellcovorin
  • Folinsäure
  • Calciumfolinat
  • Leucovorin-Kalzium
Experimental: Part 2b Cohort C2

Combination (PF-07934040 + Pembro or Sasanlimab) dose escalation/expansion in 1L NSCLC (TPS ≥ 50%)

Prescribed dose and frequency in 21-day cycles (for pembro) or 28-day cycles (for sasanlimab)

panKRAS inhibitor

Andere Namen:
  • PF-4040

immune checkpoint inhibitor (PD-1 inhibitor)

Andere Namen:
  • Keytruda
  • MK-3475
  • Lambrolizumab
  • Pembro

immune checkpoint inhibitor (PD-1 inhibitor)

Andere Namen:
  • PF-06081591
Experimental: Part 2b Cohort C3

Combination (PF-07934040 + Pembro + Platinum Chemo) dose escalation/expansion in 1L NSCLC (any TPS)

Prescribed dose and frequency in 21-day cycles

panKRAS inhibitor

Andere Namen:
  • PF-4040

immune checkpoint inhibitor (PD-1 inhibitor)

Andere Namen:
  • Keytruda
  • MK-3475
  • Lambrolizumab
  • Pembro

Can be used in Platinum-based Chemotherapy regimen

Antimetabolite

Andere Namen:
  • Alimta

Can be used as part of Platinum-based chemotherapy regimen

Platinum-based antineoplastic (alkylating agent)

Andere Namen:
  • Cisplatin
  • Platinol
  • Neoplatin

Can be used in Platinum-based chemotherapy regimen

Taxane

Andere Namen:
  • Taxol
  • Onxol

Can be used as part of a platinum-based chemotherapy regimen

platinum containing compound (alkylating agent)

Andere Namen:
  • Paraplatin
  • Stricarb

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Part 1 & 2: Incidence of Adverse Events (AEs)
Zeitfenster: Start of treatment up to 30 days after last dose or start of new anticancer therapy (whichever occurs first)

An adverse event (AE) was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship to it. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly. AEs included both serious and all non-serious AEs.

Start of treatment up to 30 days after last dose or start of new anticancer therapy (whichever occurs first)
PART 1 & 2: Number of participants with laboratory abnormalities
Zeitfenster: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first

Number of participants with laboratory test abnormalities. Laboratory test parameters included hematology, coagulation, liver function, renal function, electrolytes, clinical chemistry, and urinalysis (dipstick and microscopy).

From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
Part 1: Number of participants with Dose-limiting toxicities (DLT)
Zeitfenster: Baseline up to 28 days

Any of the prespecified AEs that are attributable to one, the other, or both study treatments, occurring in the DLT observation period are considered DLTs, excluding toxicities clearly due to underlying disease or extraneous causes

Baseline up to 28 days
Part 2: Objective Response - Number of Participants With Objective Response (alone or in combination)
Zeitfenster: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion, approximately 2 years'

Percentage of participants with objective response-based assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) for overall response rate (ORR), progression free survival (PFS), and overall survivor (OS) assessed by the Investigator.

Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion, approximately 2 years'

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Part 1 & 2: Maximum Observed Serum Concentration (Cmax)
Zeitfenster: baseline through end of Cycle 1 (All cycles are 28 days except part 2b Cohort C2 which are 21 days)

Evaluate the single and multiple dose PK of PF-07934040 as monotherapy, or in combination with other anti-tumor agents.

baseline through end of Cycle 1 (All cycles are 28 days except part 2b Cohort C2 which are 21 days)
Part 1& 2: Time to Reach Maximum Observed Serum Concentration (Tmax)
Zeitfenster: Baseline through end of Cycle 1 (All cycles are 28 days except part 2b Cohort C2 which are 21 days)

Evaluate the single and multiple dose PK of PF-07934040 as monotherapy, or in combination with other anti-tumor agents.

Baseline through end of Cycle 1 (All cycles are 28 days except part 2b Cohort C2 which are 21 days)
Part 1 & 2: Serum Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
Zeitfenster: Baseline through end of Cycle 1 (All cycles are 28 days except part 2b Cohort C2 which are 21 days)

Evaluate the single and multiple dose PK of PF-07934040 as monotherapy, or in combination with other anti-tumor agents.

Baseline through end of Cycle 1 (All cycles are 28 days except part 2b Cohort C2 which are 21 days)
Part 1 & 2: Changes in pERK levels
Zeitfenster: Baseline through end of Cycle 1 (All cycles are 28 days except part 2b Cohort C2 which are 21 days)

Evaluates the intended mechanism of action (MoA) modulation of KRAS inhibition and target engagement effect of PF-07934040 in peripheral blood of participants with advanced solid tumor malignancies.

Baseline through end of Cycle 1 (All cycles are 28 days except part 2b Cohort C2 which are 21 days)
Part 1: Objective Response - Number of Participants With Objective Response
Zeitfenster: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion, approximately 2 years

Percentage of participants with objective response-based assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) assessed by the Investigator including overall response rate (ORR), progression free survival (PFS), and overall survival (OS).

Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion, approximately 2 years
Part 1: Effect of Food on Cmax
Zeitfenster: Baseline through end of Cycle 1 (All cycles are 28 days)

Evaluate the effect of food on Cmax of PF-07934040 as monotherapy.

Baseline through end of Cycle 1 (All cycles are 28 days)
Part 1: Effect of Food on Tmax
Zeitfenster: Baseline through end of Cycle 1 (All cycles are 28 days)

Evaluate the effect of food on Tmax of PF-07934040 as monotherapy.

Baseline through end of Cycle 1 (All cycles are 28 days)
Part 1: Effect of Food on AUClast
Zeitfenster: Baseline through end of Cycle 1 (All cycles are 28 days)

Evaluate the effect of food on AUClast of PF-07934040 as monotherapy.

Baseline through end of Cycle 1 (All cycles are 28 days)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Studienleiter: Pfizer CT.gov Call Center, Pfizer

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

27. Juni 2024

Primärer Abschluss (Geschätzt)

9. Oktober 2026

Studienabschluss (Geschätzt)

9. Oktober 2026

Studienanmeldedaten

Zuerst eingereicht

29. Mai 2024

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

6. Juni 2024

Zuerst gepostet (Tatsächlich)

7. Juni 2024

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

13. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

9. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • C5421001
  • NCT06447662 (Registrierungskennung: ClinicalTrials.gov)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .